Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases
- 1 May 2006
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Journal of Clinical Immunology
- Vol. 26 (3), 265-273
- https://doi.org/10.1007/s10875-006-9021-7
Abstract
Intravenous immunoglobulin (IVIg) infusions at 3–4 week intervals are currently standard therapy in the United States for patients with primary immune deficiency diseases (PIDD). To evaluate alternative modes of immunoglobulin administration we have designed an open-label study to investigate the efficacy and safety of a subcutaneously administered immunoglobulin preparation (16% IgG) in patients with PIDD. After their final IVIg infusion, 65 patients entered a 3-month, wash-in/wash-out phase, designed to bring patients to steady-state with subcutaneously administered immunoglobulin. This was followed by 12 months of weekly SCIg infusions, at a dose determined in a pharmacokinetic substudy to provide noninferior intravascular exposure. This resulted in a mean weekly dose of 158 mg/kg, calculated to equal 137% of the previous intravenous dose. Two patients (4%) each reported 1 serious bacterial infection (pneumonia), an annual rate of 0.04 per patient-year. There were 4.43 infections of any type per patient-year. Mean trough serum IgG levels increased from 786 to 1040 mg/dL during the study, a mean increase of 39%. The most frequent treatment-related adverse event was infusion-site reaction, reported by 91% of patients; this was predominantly mild or moderate, and the incidence decreased over time. No treatment-related serious adverse events were reported. We conclude that subcutaneous administration of 16% SCIg is a safe and effective alternative to IVIg for replacement therapy of PIDD.Keywords
This publication has 30 references indexed in Scilit:
- Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at homeJournal of Allergy and Clinical Immunology, 2004
- Subcutaneous immunoglobulin replacement in primary immunodeficienciesClinical Immunology, 2004
- Immunoglobulin replacement treatment by rapid subcutaneous infusionArchives of Disease in Childhood, 1998
- Subcutaneous Administration of ImmunoglobulinsClinical Immunotherapeutics, 1996
- Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin PreparationsPublished by American Medical Association (AMA) ,1995
- Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costsThe Lancet, 1995
- The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusionsClinical and Experimental Immunology, 1993
- Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusionThe Lancet, 1991
- Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patientsAmerican Journal Of Medicine, 1986
- Anaphylactic Reactions after Gamma Globulin Administration in Patients with HypogammaglobulinemiaNew England Journal of Medicine, 1986